M&A Sector Snapshot: Pharmaceuticals takes the pulse of the pharmaceutical sector in light of an unprecedented level of deal activity in early 2014, summarizing noteworthy influences, dealmaking and predictions.
See why pharmaceuticals was the most dominant industry in the global M&A landscape for the first half of 2014. Produced by Thomson Reuters’ International Financing Review in cooperation with Merrill Corporation, M&A Sector Snapshot: Pharmaceuticals gives you insight into the drivers of pharma M&A activity, including operational cost reduction, growth ambitions, portfolio gaps and increasing pipeline confidence. You’ll also find out what regulatory changes may mean for the playing field and what prognosis bankers give the sector.
- Review of recent big-ticket transactions and transformational deals
- Graph plotting data on target M&A volumes by year and region
- Data on mega deals of Valeant, Allergan, AbbVie, GlaxoSmithKline, Novartis and other heavy hitters, including a hostile bid for a whopping US$115 billion that was withdrawn